This 2023 prospective, open-label pilot study assessed the efficacy and safety of a 0.5% silymarin-loaded antioxidant serum (SAS) as an adjunct treatment in 22 Korean patients with mild-to-moderate acne vulgaris. Over four weeks, patients applied the serum twice daily in addition to their regular acne treatments. The study reported reductions
